Cartesian Therapeutics (RNAC) Assets Average: 2016-2025
Historic Assets Average for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2025 value amounting to $380.8 million.
- Cartesian Therapeutics' Assets Average fell 5.17% to $380.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.8 million, marking a year-over-year decrease of 5.17%. This contributed to the annual value of $370.0 million for FY2024, which is 57.15% up from last year.
- Latest data reveals that Cartesian Therapeutics reported Assets Average of $380.8 million as of Q3 2025, which was down 4.57% from $399.0 million recorded in Q2 2025.
- Cartesian Therapeutics' 5-year Assets Average high stood at $445.2 million for Q4 2024, and its period low was $122.8 million during Q3 2023.
- Moreover, its 3-year median value for Assets Average was $336.5 million (2024), whereas its average is $303.4 million.
- Per our database at Business Quant, Cartesian Therapeutics' Assets Average slumped by 32.97% in 2023 and then surged by 227.06% in 2024.
- Cartesian Therapeutics' Assets Average (Quarterly) stood at $163.5 million in 2021, then climbed by 5.23% to $172.1 million in 2022, then grew by 19.45% to $205.5 million in 2023, then spiked by 116.58% to $445.2 million in 2024, then decreased by 5.17% to $380.8 million in 2025.
- Its last three reported values are $380.8 million in Q3 2025, $399.0 million for Q2 2025, and $422.1 million during Q1 2025.